Re-irradiation volumetric modulated arc therapy optimization based on cumulative biologically effective dose objectives

Nevin McVicar¹ | Steven Thomas¹ | Mitchell Liu² | Hannah Carolan² | Alanah Bergman¹

¹Department of Medical Physics, BC Cancer – Vancouver Cancer Centre, Vancouver, BC, Canada
²Department of Radiation Oncology, BC Cancer – Vancouver Cancer Centre, Vancouver, BC, Canada

Abstract
The objective of this note is to introduce a clinical tool that generates ideal base plan dose distributions to enable re-irradiation volumetric modulated arc therapy (VMAT) optimization based on cumulative biological effective dose objectives for specific organs at risk (OARs). The tool is demonstrated with a lung cancer case that required re-irradiation at our clinic. First, previous treatment dose is deformed onto the retreatment computed tomography (CT) using commercial software. Then, the in-house Matlab tool alters the deformed previous dose using radiobiological concepts on a voxel-by-voxel manner to generate an ideal base plan dose distribution. Ideal base plans that were generated using the in-house Matlab tool were compatible with the Varian Eclipse™ treatment planning system. The tool enabled optimization of VMAT re-irradiation plans using cumulative dose limits for OARs and all OAR cumulative dose objectives were met on the first optimization for the recurrent lung cancer case tested.

PACS
87

KEY WORDS
adaptive replanning, linear-quadratic model, radiobiology, VMAT dose optimization algorithms

1 | INTRODUCTION
High-dose re-irradiation has emerged as a feasible treatment option in lung cancer patients with locoregional relapse and few other treatment options. Re-irradiation of locoregional relapse is becoming more common as lung cancer patients continue to live longer. Modern radiotherapy inverse plan optimization and delivery technologies such as intensity modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT) improve sparing of organs at risk (OARs) and make high-dose re-irradiation more feasible. Still, re-irradiation introduces several complexities and plan optimization is cumbersome. For example, patient anatomy changes and dose accumulation to OARs must be accounted for. The challenge of changing patient anatomy has largely been met through rigid and deformable image registration (IR) algorithms that enable IR-guided dose transfer between planning computed tomography (CT) scans.¹

In addition, computer software capable of converting voxel doses using the linear-quadratic model (LQM)² to calculate biologically effective dose (BED) distributions is now commercially available.³, ⁴

Converting previously delivered physical dose to BED allows
radiation oncologists to account for nonlinear biological response to differing dose-per-fraction. Moreover, BED distributions are theoretically additive according to the LQM — meaning distributions from separate courses of treatment can be summed to quantify cumulative BED for each voxel. The mechanistic LQM is often considered to be over simplistic; however, it is almost universally used to adjust for fraction size because it is practical, biologically based and acceptably accurate for dose-per-fractions below 15 Gy.\(^2,8\)

Based on recent reports, a growing number of radiation oncologists are using cumulative BED distributions to guide their re-irradiation plan evaluation.\(^3,6\) Several institutions have reported OAR toxicity along with cumulative BED metrics in lung cancer patients receiving re-irradiation,\(^9,10\) with some instances of severe toxicities after delivering high cumulative dose to the aorta,\(^11,12\) esophagus,\(^9,13\) and lungs.\(^14–16\) This clinical evidence has motivated radiation oncologists to prescribe cumulative BED limits for specific OARs.\(^3,6\) While IR and dose accumulation techniques improve plan evaluation and clinical decision-making, re-irradiation plan optimization remains difficult because commercial treatment planning systems (TPSs) are not designed to optimize based on cumulative BED objectives as outlined below.

Throughout VMAT optimization, TPSs display dose volume histograms (DVHs) for OARs and planning target volumes (PTVs). Visualization of evolving DVHs during optimization enables dosimetrists to influence the optimization by interactively adjusting dose objectives. The ability to monitor and adjust dose objectives throughout optimization is essential to the quality and efficiency of VMAT planning.\(^17\) For initial irradiation plans, the evolving DVHs display total physical dose delivered over all planned fractions. For re-irradiation optimization, TPSs allow for VMAT optimization using previously delivered dose as a base plan. Throughout optimization with a base plan, displayed DVHs result from the sum of base plan and optimizing plan dose distributions and are henceforth referred to as sum DVHs. Re-irradiation plan optimization using previously delivered physical dose as a base plan may be useful when initial and re-irradiation plans deliver the same dose-per-fraction. However, when significantly different dose-per-fractions are used, sum DVHs become nonsense since nonlinear radiobiological effects are not accounted for. Thus, plan optimization is cumbersome because dosimetrists lose the ability to adjust objectives based on evolving DVHs. Furthermore, after each optimization cycle, dosimetrists or physicists must convert dose to BED to determine whether cumulative BED objectives are satisfied.\(^3,6\) Application of base plan dose is further limited in re-irradiation scenarios because optimization of uniform target dose is impossible due to the presence of heterogeneous base plan dose within the new PTV, which is henceforth referred to as PTV\(_2\).

In this technical note, we introduce a clinical tool that enables direct VMAT optimization of cumulative dose objectives using an ideal base plan dose that is compatible with a commercial TPS. Our proposed tool manipulates previously delivered dose to circumvent conventional base plan limitations and help guide VMAT optimization of re-irradiation. Specifically, ideal base plans restore the ability to monitor whether cumulative dose objectives are achieved using the evolving sum DVHs throughout optimization. The tool is demonstrated retrospectively for a lung cancer case where re-irradiation was prescribed.

## METHODS AND RESULTS

### 2A Patient data

A patient with recurrent lung cancer previously treated and retreated at our clinic was used in this study. An initial course of VMAT was used to deliver a prescription of 60 Gy in 30 fractions to a primary lung PTV (PTV\(_1\)). Approximately 3 yr later, a second primary lesion was discovered and a course of stereotactic ablative radiotherapy (SABR) was prescribed to deliver 48 Gy in four fractions to the PTV\(_2\). The clinically delivered initial course dose, referred to as D\(_1\), was used in this study along with the initial and retreatment CTs, referred to as CT\(_1\) and CT\(_2\), respectively. To guide the optimization of the re-irradiation dose distribution (D\(_2\)), a radiation oncologist retrospectively provided a list of OAR-specific α/β ratios and prioritized cumulative dose limits which are listed in both physical dose (Gy per 4 fractions) and BED (Gy\(_{α/β}\)) in Table 1.\(^{18}\)

### Table 1 Summary of biological effective dose to organs at risk.

| Priority | Organ  | α/β | BED metric | BED\(_1\) | BED\(_{D_1,CT2}\) | BED\(_2\) | BED sum | Cumulative dose limits | BED (Gy\(_{α/β}\)) | Physical (Gy/4fx) |
|----------|--------|-----|------------|-----------|-----------------|----------|---------|--------------------------|-----------------|------------------|
| 1        | Spinal canal | 2   | \(D_{\text{max}}\) (Gy) | 47.2 | 46.9 | 12.1 | 47.1 | \(D_{\text{max}} < 110.5\) | \(D_{\text{max}} < 26\) |
| 2        | PBT\(^a\) | 3   | \(D_{\text{max}}\) (Gy) | 21.8 | 21.5 | 32.2 | 34.7 | \(D_{\text{max}} < 135.7\) | \(D_{\text{max}} < 34.8\) |
| 3        | Esophagus | 3   | \(D_{\text{max}}\) (Gy) | 100.5 | 104.3 | 12.7 | 104.4 | \(D_{\text{max}} < 105\) | \(D_{\text{max}} < 30\) |
| 4        | Lungs-PTV\(^b\) | 3   | \(V_{53.3\,\text{Gy}}\) (%) | 3.5 | 1.8 | 1.3 | 3.3 | \(V_{53.3} < 10\%) | \(V_{20} < 10\%\) |
| 5        | Heart | 3   | \(D_{\text{max}}\) (Gy) | 104.6 | 107.8 | 40.5 | 107.9 | \(D_{\text{max}} < 130.3\) | \(D_{\text{max}} < 34\) |
| 6        | Skin | 3   | \(D_{\text{max}}\) (Gy) | 47.3 | 48.5 | 99.5 | 105.0 | \(D_{\text{max}} < 144\) | \(D_{\text{max}} < 36\) |

BED\(_1\) doses are reported using CT\(_1\) contours.
BED\(_{D_1,CT2}\) doses are reported using CT\(_2\) contours after warping BED\(_1\) onto CT\(_2\).
BED\(_2\) and BED sum doses are reported using CT\(_2\) contours.

\(^a\)PBT, proximal bronchial tree.
\(^b\)Lungs-PTV contours are different in CT\(_1\) and CT\(_2\) due to different PTVs.
2.B | CT1-to-CT2 deformable image registration

An overview of the re-irradiation planning workflow that incorporates the proposed tool is shown in Fig. 1. First, CT1-to-CT2 deformable IR was performed and D1 was warped onto CT2 to generate D1 onsetCT2 using a commercial intensity-based IR algorithm (MIM Software Inc., Cleveland, OH, USA). As per clinical protocol, deformable IR was performed by a medical physicist and verified independently by a second medical physicist and a radiation oncologist. Deformable IR errors are not explicitly quantified or accounted for in this workflow.

2.C | Generation of base plan

The tool is an in-house Matlab (The Mathworks Inc., Natick, MA, USA) program that manipulates D1 onsetCT2 to generate an ideal base plan dose for re-irradiation optimization, referred to as D1 baseplan. The tool requires user-specified initial course prescription (Rn1) in Gy, the number of fractions for initial (n1) and re-irradiation (n2) courses, and OAR-specific priorities and α/β ratios. In addition, the tool requires a cumulative dose limit (DL) specified in Gy per n2 fractions (DL = D1 × n2) for each OAR. The tool allows for one D1 per OAR and D1 must represent a maximum point dose limit (e.g., D1 max < DL) or a maximum dose to a specified volume limit (e.g., VDL ≤ % OAR volume).

The tool requires the digital imaging and communications in medicine (DICOM) structure file associated with CT2 to label each voxel in D1 onCT2 as a specific OAR or PTV2. In cases of overlapping contours, voxels are labeled as the highest priority structure. Since TPSs display the sum DVH (D1 baseplan + optimizing D2) throughout optimization in Gy per n2 fractions, D1 baseplan voxel dose is also specified in Gy per n2 fractions.

2.C.1 | OAR base plan dose

For each OAR, D1 onCT2 is converted voxel-by-voxel to a physical dose in Gy per n2 fractions equal to the radiobiological fraction of DL previously delivered by initial treatment. To do this, DL is converted to BED (BEDL) using the LQM formalism:

$$BED_L = D_L \times n_2 \left(1 + \frac{d_L}{\alpha/\beta}\right)$$

Similarly, D1 onCT2 is converted to BED (BEDL) for all voxels. Then, for each voxel with BED1 < BEDL the allowed re-irradiation voxel dose is defined as D allowed = D allowed × n2, with D allowed calculated using the equality:

$$BED_L - BED_1 \equiv BED_{allowed} = D_{allowed} \times n_2 \left(1 + \frac{d_{allowed}}{\alpha/\beta}\right),$$

and then, D1 baseplan voxel dose is set to D1 – D allowed.

Here, we highlight two important points regarding voxels with BED1 < BEDL that receive exactly D allowed during re-irradiation: (a) D1 baseplan + D allowed = D1 and therefore, these voxels are easily monitored on the sum DVH throughout optimization and (b) BED1 + D allowed = BEDL; hence, the sum DVH value at D1 accurately portrays whether D1 is satisfied or not. Furthermore, voxels with BED1 < BEDL that receive under D allowed will appropriately appear below D1 on the sum DVH throughout optimization, whereas voxels with BED1 < BEDL that receive over D allowed appear above...
D_i. Hence, the advantage to the dosimetrist is that evolving sum DVHs reliably illustrate whether cumulative dose objectives are met throughout optimization.

For OARs where D_i represents a maximum dose to a specified volume, some voxels will have BED_1 ≥ BED_i. For these voxels, D_{1_baseplan} voxel dose is set to the isoeffective dose delivered in n_2 fractions, referred to as D_{1,n2} where D_{1,n2} = d_{1,n2} × n_2, with d_{1,n2} calculated using the equality:

\[
\text{BED}_1 = d_1 \times n_1 \left( \frac{1 + \frac{d_1}{\alpha/\beta}}{1 + \frac{D_{1,n2}}{\alpha/\beta}} \right) = d_{1,n2} \times n_2 \left( 1 + \frac{d_{1,n2}}{\alpha/\beta} \right)
\]

The isoeffective dose conversion essentially scales D_{1_onCT2} dose to the re-irradiation fractionation such that it will correctly appear above D_i on the sum DVH throughout the entire optimization. It must be recognized that none of the OAR sum DVH values represent true physical or biological dose when D_{1_baseplan} is used. However, each sum DVH may be regarded as a LQM-scaled approximation that accurately reports whether D_i is satisfied.

2.C.2 | PTV_2 base plan dose

All voxels labeled as PTV_2 are set to an arbitrary uniform dose in D_{1_baseplan}. For practical purposes, PTV_2 voxel doses are set to 0 Gy in this case. The uniform base plan dose in PTV_2 is required to enable optimization of a uniform re-irradiation dose to PTV_2.

Finally, D_{1_baseplan} is saved as a DICOM dose file, using the original dose files’ DICOM header information. The Matlab-generated DICOM base plan dose files are then imported to the version 13.0 Eclipse™ TPS.

2.D | Re-irradiation VMAT optimization

The re-irradiation plan consisted of two full coplanar arcs placed at the center of PTV_2. For the recurrent lung case, D_{1_baseplan} was generated using tool inputs: R_{4T}/n_1 = 60/30, n_2 = 4 along with all OAR-specific priorities, α/β, and D_i listed in Table 1. Optimization dose objectives were set according to prioritized cumulative dose limits in Gy per n_2 fractions listed in Table 1. Since PTV_2 voxel dose is 0 Gy in D_{1_baseplan}, PTV_2 lower dose objective is set to R_{4T} (48 Gy).

2.E | Re-irradiation plan evaluation

After optimization, D_2 and D_{1_onCT2} were converted to BED using MIM software and the cumulative BED was calculated. Cumulative dose limits were satisfied and OAR-specific sum BED metrics are reported in Table 1. For the re-irradiation plan only, the percent volume of PTV_2 that received ≥100% of the R_{20Gy} was 99.9% and the D_{max} was 128% (61.6 Gy), which is acceptable for SABR treatment at our clinic.

3 | DISCUSSION

To our knowledge, this is the first strategy to use the previously delivered dose and radiobiological concepts to generate an ideal three-dimensional base plan for re-irradiation optimization. The impact of the ideal base plan on the final optimized dose distribution is outlined further here. In serial OARs where D_i represents a maximum point dose limit, voxels that previously received higher doses will be preferentially spared compared to voxels that received lower doses in order to achieve cumulative D_{max} < D_i in each voxel. This effect is in agreement with other published re-irradiation studies that limited cumulative maximum point dose for serial OARs such as aorta, esophagus, and spinal cord. Conversely, in parallel OARs where D_i represents a maximum dose to a specified volume limit, voxels that previously received doses > D_i will be preferentially irradiated compared to voxels that received doses < D_i in order to minimize cumulative V_{D_20Gy}. For example, when the Lung-PTV dose objective is V_{20Gy} ≤ 10%, voxels in the lung that previously received >20 Gy are not spared during re-irradiation optimization. Again, this effect is in agreement with previous findings that patients retreated with infield relapses experienced lower rates of pneumonitis compared with those retreated with out of field relapses,^{14,16} which suggests that previously irradiated lung tissue may have fibrosis and be less susceptible to radiation pneumonitis.\(^{20}\) Hence, our tool enables serial and parallel OARs to be optimized in different manners based on the type of dose objective, D_i, used. Key limitations of our algorithm are that it only supports one objective per OAR and it cannot support cumulative mean dose objectives.

As standard fractionation schemes (1.8–2 Gy per fraction) are replaced with hypofractionated stereotactic ablative radiotherapy (>6 Gy per fraction), oncologists increasingly rely on the LQM to derive optimal re-irradiation fractionation schemes and OAR dose objectives. The use of LQM-derived cumulative BED dose constraints is controversial because the additivity of BED distributions is theoretical and very difficult to validate clinically. In this work, the inherent uncertainty of LQM-derived BED values is not explicitly quantified and cumulative BED distributions should only serve to compliment careful judgment of the treating physician. Moreover, the basic LQM formalism used in this technical note does not explicitly account for the impact of ablation and/or regeneration of surrounding vasculature and stromal tissue, which is especially relevant in re-irradiation scenarios. It may be appropriate to adapt the proposed tool to employ more complex models (e.g., to account for tissue recovery between treatment courses) if it is deemed necessary by the treating physician.\(^{7,21}\) Finally, planned re-irradiation dose distributions must always be evaluated alone in addition to the cumulative BED distribution prior to re-irradiation commencement.

In this work, a tool was shown to facilitate optimization of VMAT re-irradiation plans using cumulative dose limits for OARs. Ideal base plans generated using our tool were compatible with the Varian Eclipse™ TPS and similar tools could be developed for other TPSs that accommodate base plans. The presented tool may also be used for inverse-planning of IMRT plans as long as base plans can be used during optimization. Although the underlying algorithm used to create the
ideal base plan is complex, the tool is clinically practical because it only requires simple OAR-specific inputs to generate an ideal base plan for each patient. Furthermore, use of the ideal base plan eliminates time-consuming iterations of plan optimization, dose conversion to BED and BED accumulation to verify whether cumulative dose objectives are achieved or not. Future work will aim to incorporate representation of dosimetric uncertainties associated with deformable IR errors during cumulative dose evaluation.22 Furthermore, a script will be developed using Eclipse scripting Application Programming Interface to streamline clinical use of this tool. Finally, we will investigate potential improvements in planning time required and overall plan quality introduced by the proposed planning approach.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

1. Pukala J, Johnson PB, Shah AP, et al. Benchmarking of five commercial deformable image registration algorithms for head and neck patients. J Appl Clin Med Phys. 2016;17:25–40.
2. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–694.
3. Boman E, Kapanen M, Pickup L, Lahtela SL. Importance of deformable image registration and biological dose summation in planning of radiotherapy retreatments. Med Dosim. 2017;42:296–303.
4. Lee SP, Leu MY, Smathers JB, McBride WH, Parker RG, Withers HR. Biologically effective dose distribution based on the linear quadratic model and its clinical relevance. Int J Rad Oncol Biol Phys. 1995;33:375–389.
5. Jones B, Dale RG, Deehan C, Hopkins KI, Morgan DA. The role of biologically effective dose (BED) in clinical oncology. Clin Oncol. 2001;13:71–81.
6. Jumeau R, Péguret N, Zulliger C, Moeccki R, Bourhis J, Ozsahin EM. Optimization of re-irradiation using deformable registration: a case study. BJR Case Rep. 2016;2:20150412.
7. Park C, Papiez L, Zhang S, Story M, Zimmerman RD. Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:847–852.
8. Brenner DJ. The linear-quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Sem Radiat Oncol. 2008;18:234–239.
9. Binkley MS, Hiniker SM, Chaudhuri A, et al. Dosimetric factors and toxicity in highly conformal thoracic reirradiation. Int J Radiat Oncol Biol Phys. 2016;94:808–815.
10. De Ruyscher D, Falvre-Finn C, Le Pechoux C, Peeters S, Belderbos J. High-dose re-irradiation following radical radiotherapy for non-small-cell lung cancer. Lancet Oncol. 2014;15:e620–e624.
11. Evans JD, Gomez DR, Amini A, et al. Aortic dose constraints when reirradiating thoracic tumors. Radiother Oncol. 2013;106:327–332.
12. Kilburn JM, Kuremsky JG, Blackstock AW, et al. Thoracic re-irradiation using stereotactic body radiotherapy (SBRT) techniques as first or second course of treatment. Radiother Oncol. 2014;110:505–510.
13. Griffioen GH, Dahele M, de Haan PF, van de Ven PM, Slotman BJ, Senan S. High-dose, conventionally fractionated thoracic reirradiation for lung tumors. Lung Cancer. 2014;83:356–362.
14. Liu H, Zhang X, Vinogradskiy YY, Swisher SG, Komaki R, Chang JY. Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy. Int J Radiat Oncol Biol Phys. 2012;84:1017–1023.
15. McAvoy S, Ciura K, Wei C, et al. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy; predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014;90:819–827.
16. Ren C, Ji T, Liu T, Dang J, Li G. The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation. Radiat Oncol. 2018;13:69.
17. Otto K. Volumetric modulated arc therapy; IMRT in a single gantry arc. Med Phys. 2008;35:310–317.
18. Videtic GM, Hu C, Singh AK, et al. NRG Oncology RTOG 0915 (NCCTG N0927): a randomized phase II study comparing 2 stereotactic body radiation therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;93:757.
19. Douglas BG, Fowler JF. The effect of multiple small doses of x rays on skin reactions in the mouse and a basic interpretation. Radiat Res. 1976;66:401–426.
20. Kelly P, Balter PA, Rebueno N, et al. Stereotactic body radiation therapy for patients with lung cancer previously treated with thoracic radiation. Int J Radiat Oncol Biol Phys. 2010;78:1387–1393.
21. Jones B, Hopewell JW. Alternative models for estimating the radiobiological tumor control probability for stereotactic body radiation therapy (SBRT). Int J Radiat Oncol Biol Phys. 2014;90:731–741.
22. Vickress J, Battista J, Barnett R, Yartsev S. Representing the dosimetric impact of deformable image registration errors. Phys Med Biol. 2017;62:N391–N403.